INOVIO PHARMACEUTICALS, INC.
For the period ended Dec 31, 2024. Filed Mar 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 18, 2025
INO$1.51+24.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $65,813,297 | $14,310,862 |
| Short-term investments | 28,300,232 | 130,982,913 |
| Accounts receivable from affiliated entities | 1,199,056 | 2,405,228 |
| Prepaid expenses and other current assets, including with affiliated entity | 2,517,465 | 5,414,097 |
| Total current assets | 97,830,050 | 153,113,100 |
| Fixed assets, net | 3,659,818 | 4,960,986 |
| Investments in affiliated entity | 1,613,844 | 2,780,287 |
| Operating lease right-of-use assets | 8,113,840 | 9,491,735 |
| Other assets | 1,979,654 | 605,315 |
| Total assets | $113,197,206 | $170,951,423 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $16,200,013 | $19,847,744 |
| Accounts payable and accrued expenses due to affiliated entities | 1,351,163 | 1,070,519 |
| Accrued clinical trial expenses | 2,021,860 | 2,365,382 |
| Common stock warrant liability | 13,255,188 | — |
| Operating lease liability | 2,497,360 | 2,406,522 |
| Grant funding liability, including from affiliated entity | — | 109,407 |
| Convertible senior notes | — | 16,770,654 |
| Total current liabilities | 35,325,584 | 42,570,228 |
| Operating lease liability, net of current portion | 9,367,827 | 11,032,066 |
| Total liabilities | 44,693,411 | 53,602,294 |
| Commitments and contingencies | ||
| Inovio Pharmaceuticals, Inc. stockholders’ equity: | ||
| Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December 31, 2024 and 2023 | — | — |
| Common stock—par value $0.001; Authorized shares: 600,000,000 at December 31, 2024 and 2023, issued and outstanding: 36,099,991 at December 31, 2024 and 22,793,075 at December 31, 2023 | 36,099 | 22,792 |
| Additional paid-in capital | 1,799,362,625 | 1,740,954,074 |
| Accumulated deficit | (1,730,219,262) | (1,622,965,136) |
| Accumulated other comprehensive loss | (675,667) | (662,601) |
| Total Inovio Pharmaceuticals, Inc. stockholders’ equity | 68,503,795 | 117,349,129 |
| Total liabilities and stockholders’ equity | $113,197,206 | $170,951,423 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.